Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;20(2):215-224.
doi: 10.1007/s12017-018-8493-y. Epub 2018 May 4.

The Dynamics of Neurosteroids and Sex-Related Hormones in the Pathogenesis of Alzheimer's Disease

Affiliations
Review

The Dynamics of Neurosteroids and Sex-Related Hormones in the Pathogenesis of Alzheimer's Disease

Milad Hasanpour et al. Neuromolecular Med. 2018 Jun.

Abstract

Alzheimer's disease (AD) is commonly diagnosed by vast extracellular amyloid deposits and existence of intracellular neurofibrillary tangles. In accordance with the literature, age-related loss of sex steroid hormones in either males or females was found in relation to AD subjects. The dynamics of these hormones have been previously described in both physiological and pathological conditions with the evidence of changes in various intracellular signalings regarding the neurodegenerative disease. The potent protective effects of sex steroid hormones and their synthetic analogs are indicative of the decrease in the accumulated levels of intercellular beta-amyloid (Aβ) protein and an increase of specific proteases activity, resulting in the improvement of pathological features. In the current review, we focused on the dynamic of signaling pathway related to sex steroid hormones. It is logical to hypothesize that androgen hormones have regulatory actions on the kinetics of Aβ which make them as a promising preventive approach for neurodegenerative diseases in the near future.

Keywords: Alzheimer’s disease; Neurosteroids; Sex-related hormones; Signaling pathway.

PubMed Disclaimer

References

    1. Crit Rev Neurobiol. 2004;16(1-2):67-74 - PubMed
    1. Age (Dordr). 2009 Jun;31(2):143-53 - PubMed
    1. J Mol Neurosci. 2016 Nov;60(3):336-348 - PubMed
    1. Drug Deliv. 2015;22(7):918-30 - PubMed
    1. JAMA. 2001 May 2;285(17):2195-6 - PubMed

MeSH terms

LinkOut - more resources